ARTIVION (AORT) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$21.26
+0.2% on the day
-47.3% over 12 months
52-week range $20.10 – $47.63
Share price and insider trades
AORT closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$20.7M
Insiders buying0
Insiders selling8
ARTIVION insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $20.7M of AORT stock on the open market.
Get emailed when insiders cluster-buy stocks like AORT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
AORT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $2.6M | 7 |
| Q2 2026 | — | 0 | $911K | 2 |
| Q1 2026 | — | 0 | $5.0M | 25 |
| Q4 2025 | — | 0 | $12.2M | 30 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.8×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 ARTIVION, INC. insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $20.7M. 8 of 64 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
AORT earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 6, 2026 | +4.9% | None | +3.6%S&P +0.5% | -5.7% |
| May 7, 2026 | -5.0% | None | -26.8%S&P +0.5% | -20.8% |
| Feb 12, 2026 | -3.3% | None | -8.7%S&P -1.5% | -0.6% |
| Nov 6, 2025 | +10.0% | None | -3.5%S&P -1.0% | -0.6% |
| Aug 7, 2025 | +6.2% | None | +26.9%S&P +0.7% | +6.2% |
| May 5, 2025 | +1.7% | None | +17.5%S&P -1.4% | +6.2% |
| Feb 24, 2025 | -9.6% | None | -9.6%S&P -1.0% | -4.1% |
| Nov 7, 2024 | +11.0% | None | -2.5%S&P +1.2% | +3.3% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 11SEC | Andrew M GreenSvp, Regulatory And Quality | Sell | 11,48040,160 held (−22%) | $24.97 | $287K | -14.9% | — |
| Sep 4SEC | Andrew M GreenSvp, Regulatory And Quality | Sell | 6,51053,133 held (−11%) | $27.27 | $178K | -22.0% | — |
| Sep 4SEC | Andrew M GreenSvp, Regulatory And Quality | Sell | 1,49351,640 held (−3%) | $26.02 | $39K | -18.3% | — |
| Aug 20SEC | James P MackinCEO, President | Sell | 70,000877,275 held (−7%) | $28.96 | $2.0M | -26.6% | — |
| Aug 17SEC | Lance A BerryCFO, COO | Sell | 715210,112 held (−0%) | $28.55 | $20K | -25.5% | — |
| Aug 17SEC | Andrew M GreenSvp, Regulatory And Quality | Sell | 61659,643 held (−1%) | $28.55 | $18K | -25.5% | — |
| Aug 12SEC | Jean F HollowayGeneral Counsel | Sell | 977184,118 held (−1%) | $28.49 | $28K | -25.4% | — |
| Jun 15SEC | Andrew M GreenSvp, Regulatory And Quality | Sell Plan | 30,00060,259 held (−33%) | $20.69 | $621K | +2.8% | — |
| Jun 15SEC | Andrew M GreenSvp, Regulatory And Quality | Sell Plan | 14,00160,259 held (−19%) | $20.71 | $290K | +2.7% | — |
| Mar 4SEC | James P MackinCEO, President | Sell | 17,887947,275 held (−2%) | $37.78 | $676K | -43.7% | — |
| Mar 4SEC | Jean F HollowayGeneral Counsel | Sell | 8,962185,095 held (−5%) | $38.00 | $341K | -44.1% | — |
| Mar 4SEC | Lance A BerryCFO, COO | Sell | 6,316210,827 held (−3%) | $37.78 | $239K | -43.7% | — |
| Mar 4SEC | John E DavisChief Commercial Officer | Sell | 4,573230,794 held (−2%) | $37.78 | $173K | -43.7% | — |
| Mar 4SEC | Jean F HollowayGeneral Counsel | Sell | 3,843194,057 held (−2%) | $37.78 | $145K | -43.7% | — |
| Mar 4SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 2,14960,097 held (−3%) | $37.78 | $81K | -43.7% | — |
| Mar 4SEC | Amy HortonVp, Chief Accounting Officer | Sell | 901139,088 held (−1%) | $37.78 | $34K | -43.7% | — |
| Mar 3SEC | James P MackinCEO, President | Sell | 14,911848,214 held (−2%) | $38.02 | $567K | -44.1% | — |
| Mar 3SEC | Lance A BerryCFO, COO | Sell | 5,178176,269 held (−3%) | $38.02 | $197K | -44.1% | — |
| Mar 3SEC | John E DavisChief Commercial Officer | Sell | 2,784206,522 held (−1%) | $38.02 | $106K | -44.1% | — |
| Mar 3SEC | Jean F HollowayGeneral Counsel | Sell | 2,183170,105 held (−1%) | $38.02 | $83K | -44.1% | — |
| Mar 3SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 1,51340,408 held (−4%) | $38.02 | $58K | -44.1% | — |
| Mar 3SEC | Amy HortonVp, Chief Accounting Officer | Sell | 641132,514 held (−0%) | $38.02 | $24K | -44.1% | — |
| Feb 25SEC | James P MackinCEO, President | Sell | 20,962780,031 held (−3%) | $37.59 | $788K | -43.4% | — |
| Feb 25SEC | James P MackinCEO, President | Sell | 13,936766,095 held (−2%) | $35.69 | $497K | -40.4% | — |
| Feb 25SEC | Lance A BerryCFO, COO | Sell | 4,981148,450 held (−3%) | $37.59 | $187K | -43.4% | — |
| Feb 25SEC | Lance A BerryCFO, COO | Sell | 4,485143,965 held (−3%) | $35.69 | $160K | -40.4% | — |
| Feb 25SEC | John E DavisChief Commercial Officer | Sell | 3,773190,943 held (−2%) | $37.59 | $142K | -43.4% | — |
| Feb 25SEC | Jean F HollowayGeneral Counsel | Sell | 3,079153,871 held (−2%) | $37.59 | $116K | -43.4% | — |
| Feb 25SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 2,42343,180 held (−5%) | $37.59 | $91K | -43.4% | — |
| Feb 25SEC | John E DavisChief Commercial Officer | Sell | 2,075188,868 held (−1%) | $35.69 | $74K | -40.4% | — |
| Feb 25SEC | Amy HortonVp, Chief Accounting Officer | Sell | 1,731128,327 held (−1%) | $37.59 | $65K | -43.4% | — |
| Feb 25SEC | Jean F HollowayGeneral Counsel | Sell | 1,668152,203 held (−1%) | $35.69 | $60K | -40.4% | — |
| Feb 25SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 1,25941,921 held (−3%) | $35.69 | $45K | -40.4% | — |
| Feb 25SEC | Amy HortonVp, Chief Accounting Officer | Sell | 830127,497 held (−1%) | $35.69 | $30K | -40.4% | — |
| Dec 17SEC | John E DavisChief Commercial Officer | Sell | 5,000193,842 held (−3%) | $45.11 | $226K | -52.9% | — |
| Dec 9SEC | Amy HortonVp, Chief Accounting Officer | Sell | 4,572130,058 held (−3%) | $44.42 | $203K | -52.1% | — |
| Dec 4SEC | James P MackinCEO, President | Sell Plan | 30,921800,993 held (−4%) | $45.46 | $1.4M | -53.2% | — |
| Dec 4SEC | Jean F HollowayGeneral Counsel | Sell | 5,267156,093 held (−3%) | $45.30 | $239K | -53.1% | — |
| Dec 4SEC | Jean F HollowayGeneral Counsel | Sell | 2,048161,360 held (−1%) | $45.30 | $93K | -53.1% | — |
| Dec 3SEC | James P MackinCEO, President | Sell Plan | 30,921800,993 held (−4%) | $45.56 | $1.4M | -53.3% | — |
| Nov 24SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 18,70553,123 held (−26%) | $44.91 | $840K | -52.7% | — |
| Nov 24SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 14,58650,468 held (−22%) | $44.92 | $655K | -52.7% | — |
| Nov 24SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 11,88844,753 held (−21%) | $44.14 | $525K | -51.8% | — |
| Nov 24SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 8,37044,753 held (−16%) | $45.35 | $380K | -53.1% | — |
| Nov 24SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 5,71544,753 held (−11%) | $45.35 | $259K | -53.1% | — |
| Nov 24SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 2,03344,753 held (−4%) | $44.32 | $90K | -52.0% | — |
| Nov 24SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 1,35544,753 held (−3%) | $44.28 | $60K | -52.0% | — |
| Nov 19SEC | Elizabeth A HoffDirector | Sell | 4,20027,189 held (−13%) | $45.10 | $189K | -52.9% | — |
| Nov 18SEC | Jean F HollowayGeneral Counsel | Sell Plan | 6,394163,408 held (−4%) | $45.17 | $289K | -52.9% | — |
| Nov 18SEC | John E DavisChief Commercial Officer | Sell Plan | 6,394198,842 held (−3%) | $45.17 | $289K | -52.9% | — |
| Nov 18SEC | Jean F HollowayGeneral Counsel | Sell Plan | 6,393163,408 held (−4%) | $45.00 | $288K | -52.8% | — |
| Nov 18SEC | John E DavisChief Commercial Officer | Sell Plan | 6,393198,842 held (−3%) | $44.67 | $286K | -52.4% | — |
| Nov 18SEC | Amy HortonVp, Chief Accounting Officer | Sell | 6,000135,380 held (−4%) | $45.73 | $274K | -53.5% | — |
| Nov 14SEC | James P MackinCEO, President | Sell | 34,210800,993 held (−4%) | $45.86 | $1.6M | -53.6% | — |
| Nov 14SEC | John E DavisChief Commercial Officer | Sell | 6,563198,842 held (−3%) | $45.86 | $301K | -53.6% | — |
| Nov 14SEC | Jean F HollowayGeneral Counsel | Sell | 5,761163,408 held (−3%) | $45.86 | $264K | -53.6% | — |
| Nov 14SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 4,99356,641 held (−8%) | $45.86 | $229K | -53.6% | — |
| Nov 14SEC | Amy HortonVp, Chief Accounting Officer | Sell | 3,482141,380 held (−2%) | $45.86 | $160K | -53.6% | — |
| Nov 12SEC | James P MackinCEO, President | Sell | 17,580835,203 held (−2%) | $44.62 | $784K | -52.4% | — |
| Nov 12SEC | Jean F HollowayGeneral Counsel | Sell | 10,000169,169 held (−6%) | $46.18 | $462K | -54.0% | — |
| Nov 12SEC | John E DavisChief Commercial Officer | Sell | 3,373205,405 held (−2%) | $44.62 | $151K | -52.4% | — |
| Nov 12SEC | Jean F HollowayGeneral Counsel | Sell | 2,960169,169 held (−2%) | $44.62 | $132K | -52.4% | — |
| Nov 12SEC | Marshall S. StantonSvp, Clinical & Md Affair | Sell | 2,56661,634 held (−4%) | $44.62 | $114K | -52.4% | — |
| Nov 12SEC | Amy HortonVp, Chief Accounting Officer | Sell | 1,789144,862 held (−1%) | $44.62 | $80K | -52.4% | — |
Insiders at ARTIVION, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| James P MackinCEO, President | — | $9.7M | Aug 20, 2026 | — |
| Marshall S. StantonSvp, Clinical & Md Affair | — | $3.4M | Mar 4, 2026 | — |
| Jean F HollowayGeneral Counsel | — | $2.5M | Aug 12, 2026 | — |
| John E DavisChief Commercial Officer | — | $1.7M | Mar 4, 2026 | — |
| Andrew M GreenSvp, Regulatory And Quality | — | $1.4M | Sep 11, 2026 | — |
| Amy HortonVp, Chief Accounting Officer | — | $870K | Mar 4, 2026 | — |
| Lance A BerryCFO, COO | — | $803K | Aug 17, 2026 | — |
| Elizabeth A HoffDirector | — | $189K | Nov 19, 2025 | — |
AORT stock: common questions
Are ARTIVION, INC. insiders buying AORT stock?
In the past 12 months, 0 insiders reported open-market purchases of AORT worth $0.
Are ARTIVION, INC. insiders selling AORT stock?
8 insiders reported sales worth $20.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is AORT's 52-week range?
Over the past year AORT has traded between $20.10 and $47.63. It last closed at $21.26 on Oct 9, 2026.